124 related articles for article (PubMed ID: 1591693)
41. Augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes by the streptococcal preparation OK432.
Uchida A
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):81-4. PubMed ID: 2423823
[TBL] [Abstract][Full Text] [Related]
42. Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.
Wakasugi H; Oshimi K; Miyata M; Morioka Y
J Clin Immunol; 1981 Jul; 1(3):154-62. PubMed ID: 6174541
[TBL] [Abstract][Full Text] [Related]
43. Effect of OK-432 on cytotoxic activity in cancer patients without tumor burden.
Fujieda S; Saito H; Isobe Y; Nakagawara G; Nishi O; Nagahara K; Watanabe Y; Hoshino T
Anticancer Res; 1992; 12(6B):1941-5. PubMed ID: 1341892
[TBL] [Abstract][Full Text] [Related]
44. Lymphocyte cytotoxicity against autologous bladder tumor cells in humans, investigated by use of a chromium-51 release assay.
Jacobsen F
Acta Pathol Microbiol Scand C; 1981 Jun; 89(3):175-80. PubMed ID: 7315355
[TBL] [Abstract][Full Text] [Related]
45. In vitro induction of perforin mRNA and cytotoxic activities in human splenocytes by the streptococcal preparation, OK-432.
Kataoka K; Naomoto Y; Orita K
Jpn J Clin Oncol; 1991 Oct; 21(5):330-3. PubMed ID: 1753412
[TBL] [Abstract][Full Text] [Related]
46. Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432).
Hojo H; Hashimoto Y
Gan; 1981 Oct; 72(5):692-9. PubMed ID: 7327369
[TBL] [Abstract][Full Text] [Related]
47. Induction by OK-432 of lymphokine activated killer precursor cells in hepatocellular carcinoma.
Aramaki M; Kim YI; Shimoda K; Nakashima K; Okada K; Kobayashi M
Hepatogastroenterology; 1994 Aug; 41(4):363-6. PubMed ID: 7959572
[TBL] [Abstract][Full Text] [Related]
48. Antitumor killer lymphocytes in the peripheral blood of a patient with transitional cell carcinoma of the bladder.
Kim CJ; Yuasa T; Kushima R; Tomoyoshi T; Seto A
Int J Urol; 1998 May; 5(3):230-6. PubMed ID: 9624553
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of streptococcal preparation (OK-432) local injection in patients with urinary bladder carcinoma.
Nishio S; Izeki T; Wada S; Morikawa Y; Yasumoto R; Maekawa M
Osaka City Med J; 1980; 26(1):47-59. PubMed ID: 7267092
[No Abstract] [Full Text] [Related]
50. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
Nakayama F; Iwagaki H; Gouchi A; Hizuta A; Isozaki H; Takakura N; Tanaka N
J Med; 1998; 29(3-4):199-215. PubMed ID: 9865458
[TBL] [Abstract][Full Text] [Related]
51. Generation of cytotoxic factor by human large granular lymphocytes during interaction with autologous tumor cells: lysis of fresh human tumor cells.
Uchida A; Klein E
J Natl Cancer Inst; 1988 Nov; 80(17):1398-403. PubMed ID: 3262773
[TBL] [Abstract][Full Text] [Related]
52. [Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes].
Kan N; Okino T; Nakanishi M; Satou K; Mise K; Ohgaki K; Hori T; Kodama H; Tobe T
Hum Cell; 1988 Sep; 1(3):289-96. PubMed ID: 2979206
[TBL] [Abstract][Full Text] [Related]
53. Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins.
Mazumder A; Grimm EA; Zhang HZ; Rosenberg SA
Cancer Res; 1982 Mar; 42(3):913-8. PubMed ID: 7059990
[TBL] [Abstract][Full Text] [Related]
54. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes.
Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
J Neurosurg; 1986 Jan; 64(1):114-7. PubMed ID: 3001247
[TBL] [Abstract][Full Text] [Related]
55. Augmentation of antitumor immunity in regional lymph nodes by local immunotherapy.
Sakita I; Monden T; Nagaoka H; Katsumoto Y; Wakasugi T; Tomita N; Takeda T; Kobayashi T; Shimano T; Mori T
Biotherapy; 1993; 6(2):103-12. PubMed ID: 8398569
[TBL] [Abstract][Full Text] [Related]
56. [Effective mechanisms of BRM, with special reference to induction of autologous tumor cell-killing (ATK) activity by OK-432].
Hoshino T; Uchida A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1277-84. PubMed ID: 3488024
[TBL] [Abstract][Full Text] [Related]
57. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer.
Watanabe Y; Hashizume Y; Shimizu J; Yoshida M; Watanabe S; Iwa T; Sakai S; Migita S; Sato H; Murayama T
Am Rev Respir Dis; 1990 Oct; 142(4):769-74. PubMed ID: 2221581
[TBL] [Abstract][Full Text] [Related]
58. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
Pisani RJ; Krco CJ; Wold LE; McKean DJ
Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
[TBL] [Abstract][Full Text] [Related]
59. Augmentation in cytotoxicity of lymphnode lymphocytes by OK-432.
Tanaka N; Gotoh K; Kobayashi G; Gouchi A; Orita K
Int J Immunopharmacol; 1994 Feb; 16(2):131-5. PubMed ID: 8181902
[TBL] [Abstract][Full Text] [Related]
60. Effects of immunostimulants on the in vitro generation of cytotoxic lymphocytes against cervical cancer cell lines.
Mashiba H; Matsunaga K; Jimi S
Jpn J Exp Med; 1983 Oct; 53(5):235-41. PubMed ID: 6381820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
